Inogen, Inc (NASDAQ:INGN) Short Interest Update

Inogen, Inc (NASDAQ:INGN) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 973,130 shares, an increase of 18.9% from the January 29th total of 818,449 shares. Based on an average daily trading volume, of 267,212 shares, the short-interest ratio is currently 3.6 days. Approximately 3.6% of the company’s shares are sold short. Approximately 3.6% of the company’s shares are sold short. Based on an average daily trading volume, of 267,212 shares, the short-interest ratio is currently 3.6 days.

Inogen Stock Up 3.8%

Shares of NASDAQ:INGN opened at $6.55 on Friday. The firm has a market cap of $178.36 million, a price-to-earnings ratio of -7.62 and a beta of 1.77. Inogen has a 12 month low of $5.34 and a 12 month high of $9.13. The company’s fifty day simple moving average is $6.20 and its 200 day simple moving average is $7.21.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.10. The firm had revenue of $81.72 million for the quarter, compared to the consensus estimate of $82.00 million. Inogen had a negative return on equity of 11.56% and a negative net margin of 6.52%. Research analysts expect that Inogen will post -1.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inogen

Several hedge funds have recently made changes to their positions in the business. Quarry LP bought a new stake in shares of Inogen in the fourth quarter worth $27,000. Torren Management LLC bought a new stake in Inogen during the 4th quarter worth about $51,000. Prelude Capital Management LLC bought a new stake in Inogen during the 3rd quarter worth about $82,000. Corient Private Wealth LLC acquired a new position in shares of Inogen during the 4th quarter worth about $84,000. Finally, MetLife Investment Management LLC grew its holdings in shares of Inogen by 72.2% in the 4th quarter. MetLife Investment Management LLC now owns 12,699 shares of the medical technology company’s stock valued at $85,000 after acquiring an additional 5,325 shares in the last quarter. 89.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Inogen presently has an average rating of “Hold” and an average target price of $11.00.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.